Professional
Added to YB: 2025-02-14
Pitch date: 2025-01-26
FNCH [bullish]
Finch Therapeutics Group, Inc.
+23.01%
current return
Author Info
No bio for this author
Company Info
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
Market Cap
$19.4M
Pitch Price
$11.37
Price Target
75.00 (+436%)
Dividend
N/A
EV/EBITDA
-1.77
P/E
-1.37
EV/Sales
N/A
Sector
Biotechnology
Category
special_situation
Arquitos Capital Management New Position: Finch Therapeutics Group, Inc.
FNCH: Patent dispute with Ferring, jury awarded $30M + future royalties. Potential for enhanced damages (2.2x avg). Judge decision expected Q1. Downside limited, upside material. $20M market cap vs. $25-75/share potential value. Microbiome pioneer, now patent-focused. $10M net cash.
Read full article (3 min)